Compare Neurocrine Biosciences Inc (NBIX) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Banco Santander SA — how do they compare? Neurocrine Biosciences Inc trades at $158.09 (market cap $16.46B), while Banco Santander SA trades at $14.86 (market cap $211.63B). The key difference: Banco Santander SA is far larger — about 12.9× Neurocrine Biosciences Inc's market cap, and Banco Santander SA pays a 1.89% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SAN | |
|---|---|---|
Market Cap | $16.46B | $211.63B |
Sector | Health | Financials |
52-Week High | $185.50 | $14.71 |
52-Week Low | $123.10 | $9.37 |
Enterprise Value | $16.48B | — |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Banco Santander (SAN) trades at $14.69, showing minimal daily movement with a slight decline of 0.07%. The stock maintains a bullish technical signal supported by moving averages, while oscillators indicate neutral momentum. Fundamentally, the company reported strong profitability with a 26.25% net income margin and record quarterly profits in Q2 2026. Recent developments include Federal Reserve approval for the $12 billion Webster Bank acquisition, positioning Santander for strategic expansion.
The outlook remains positive with analyst consensus favoring Buy ratings (64%) and the company achieving Spain's most valuable listed company status. Key risks include volatile cash flow trends with negative operating cash flow in 2024-2025 and restructuring charges from recent acquisitions. Revenue growth is projected to reach $61.9B in 2026, supporting continued investor confidence despite near-term earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
